Humanised anti-PTHrP antibody

Drug Profile

Humanised anti-PTHrP antibody

Alternative Names: Anti-PTHrP humanised monoclonal antibody; CAL

Latest Information Update: 15 May 2006

Price : $50

At a glance

  • Originator Chugai Pharmaceutical
  • Class Monoclonal antibodies
  • Mechanism of Action Parathyroid hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Suspended Cancer metastases; Malignant hypercalcaemia

Most Recent Events

  • 26 Oct 2005 Chugai has completed a phase I trial in malignant hypercalcemia in Japan
  • 05 May 2004 Phase-I/II clinical trials in Malignant hypercalcaemia in Japan (Injection)
  • 27 Apr 2004 Phase-II clinical trials in Cancer metastases in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top